VALN trades 104.5% below Wall Street's consensus target of $11.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes VALN achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 2 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 22, 2026, Valneva SE (VALN) has a Wall Street consensus price target of $11.00, based on estimates from 2 covering analysts. With the stock currently trading at $5.38, this represents a potential upside of +104.5%. The company has a market capitalization of $463M.
Analyst price targets range from a low of $11.00 to a high of $11.00, representing a 0% spread in expectations. The median target of $11.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 2 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, VALN trades at a trailing P/E of -3.6x. Analysts expect EPS to grow +52.1% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
NVAXNovavax, Inc. | $1.5B | $9.13 | $18.00 | +97.2% | Buy | — | 23 |
DYAIDyadic International, Inc. | $28M | $0.78 | — | — | — | — | — |
IBRXImmunityBio, Inc. | $7.7B | $7.36 | $13.00 | +76.6% | Buy | — | 5 |
SIGASIGA Technologies, Inc. | $310M | $4.32 | — | — | Buy | 2.5x | 1 |
PFEPfizer Inc. | $143.5B | $25.22 | $26.75 | +6.1% | Hold | 8.5x | 39 |
MRKMerck & Co., Inc. | $281.2B | $113.87 | $131.58 | +15.6% | Buy | 22.2x | 37 |
GSKGSK plc | $101.9B | $50.67 | $52.45 | +3.5% | Hold | 14.0x | 29 |
SNYSanofi | $102.4B | $42.38 | $51.00 | +20.3% | Buy | 10.1x | 27 |
BNTXBioNTech SE | $23.0B | $90.89 | $132.33 | +45.6% | Buy | — | 24 |
MRNAModerna, Inc. | $25.4B | $63.96 | $40.29 | -37.0% | Hold | — | 27 |
Quick answers to the most common questions about buying VALN stock.
The consensus Wall Street price target for VALN is $11, representing 104.5% upside from the current price of $5.38. With 2 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
VALN has a consensus rating of "Buy" based on 2 Wall Street analysts. The rating breakdown is predominantly bullish, with 2 Buy/Strong Buy ratings. The consensus 12-month price target of $11 implies 104.5% upside from current levels.
VALN's current price is $5.38 with a consensus target of $11 (104.5% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $11 for VALN, while the most conservative target is $11. The consensus of $11 represents the median expectation. These targets typically reflect 12-month expectations.
VALN is lightly followed, with 2 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month VALN stock forecast based on 2 Wall Street analysts shows a consensus price target of $11, with estimates ranging from $11 (bear case) to $11 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on VALN, with a "Buy" consensus rating and $11 price target (104.5% upside). 2 of 2 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
VALN analyst price targets range from $11 to $11, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $11 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.